Format

Send to

Choose Destination
Expert Rev Clin Pharmacol. 2016 Jul;9(7):927-41. doi: 10.1586/17512433.2016.1172208. Epub 2016 Apr 14.

Targeted therapeutics for severe refractory asthma: monoclonal antibodies.

Author information

1
a Centre of Excellence in Severe Asthma, Hunter Medical Research Institute and Priority Research Centre for Healthy Lungs , The University of Newcastle , Newcastle , Australia.
2
b Department of Respiratory and Sleep Medicine , John Hunter Hospital , Newcastle , Australia.

Abstract

Severe asthma is a complex multifactorial disease that requires specialist multidisciplinary input for optimal clinical outcomes. Following multidimensional assessment for optimisation of current therapy, self-management skills and comorbidities, all patients should be accurately phenotyped. Only after this assessment has been completed should new monoclonal antibody therapies be considered. In this review, we summarise the new antibody approaches targeting identified pathological pathways in severe refractory asthma.

KEYWORDS:

Severe asthma; biomarker; monoclonal; multidimensional assessment; phenotype; targeted therapy; treatment-refractory asthma

PMID:
27018798
DOI:
10.1586/17512433.2016.1172208
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center